Recent Updates
Recently added Catalysts

Octreotide LAR Depot

Phase 2

Gastrointestinal Bleeding | Peptides | Gastrointestinal |Novartis AG|Trials Updated: Feb 3, 2017

Octreotide LAR Depot development status

Highest phase Phase 2 run by Lexicon Pharmaceuticals (NCT00853047)
Phase scored for NVSPhase 1
Registered trials 2 across 2 sponsors since Feb 2009

Octreotide LAR Depot target and mechanism

Molecular targetSSTR5, SSTR2, SSTR4, SSTR1, SSTR3
Target classAgonist
ModalityPeptides

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDDMC
Total Trials1
Total Enrollment10

FDA Designations

No designations recorded

Octreotide LAR Depot clinical trials

Octreotide LAR Depot · 1 trial · 1 indication

Phase 1 1
NCT01707225Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)Gastrointestinal Bleeding
COMPLETED10 Analytics
PHASE1COMPLETED
Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)
Gastrointestinal BleedingUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Side-Effects
24 weeks

Cardiovascular: Sinus bradycardia (19% to 25%) Hypertension (≤13%) conduction abnormalities (9% to 10%) Central nervous system: Fatigue (1% to 32%) headache (6% to 30%) malaise (16% to 20%) fever (16% to 20%) dizziness (5% to 20%) Pain (4% to 15%) Dermatologic: Pruritus (≤18%) Rash (15%; depot formulation) alopecia (≤13%) Endocrine \& metabolic: Hyperglycemia (2% to 27%) Gastrointestinal: Abdominal pain (5% to 61%) loose stools (5% to 61%) nausea (5% to 61%) diarrhea (34% to 58%) flatulence (≤38%) cholelithiasis (13% to 38%; length of therapy dependent) constipation (9% to 21%) vomiting (4% to 21%) Hematologic Anemia (5-15%) Local: Injection site pain (2% to 50%; dose and formulation related) Neuromuscular \& skeletal: Back pain (1% to 27%) arthropathy (8% to 19%) myalgia (≤18%) Renal Kidney Stones (5-15%) Respiratory: Upper respiratory infection (10% to 23%) Miscellaneous: flu symptoms (1% to 20%)

Secondary Endpoints

Need for Blood Transfusion and Hospital Admission for GI Bleed
24 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Octreotide LAR DepotEXPERIMENTALOnce enrolled in the study subjects will receive a monthly intra-muscular injection of 20mg of octreotide LAR at each study visit for 24 weeks and will be followed for a total of 36 weeks.

Interventions

NameTypeDescription
Octreotide LAR DepotDRUGThe subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * LVAD insertion as bridge to transplant or destination * 18 years of age or older Exclusion Criteria: * Poorly controlled diabetes, A1C greater than 8% * Poorly controlled hypothyroidism, TSH \> upper limit of normal (5.5) * End Stage Renal Disease (ESRD) requiring dialysis *...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Octreotide LAR Depot

What is Octreotide LAR Depot used for?

Octreotide LAR Depot is being studied for the prevention of gastrointestinal bleeding in patients with a left ventricular assist device (LVAD). It is an investigational therapy in Phase 1 development for this indication, and it has not been approved for this use.

What does Octreotide LAR Depot target?

Octreotide LAR Depot targets somatostatin receptors SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5. It acts as an agonist at these receptors, meaning it activates them. This receptor activity is the basis for its development in gastrointestinal bleeding associated with LVAD support.

Who is developing Octreotide LAR Depot?

Octreotide LAR Depot is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the company responsible for the clinical development of this asset.

What phase is Octreotide LAR Depot in?

Octreotide LAR Depot is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA for the prevention of gastrointestinal bleeding in patients with a left ventricular assist device.

What clinical trials is Octreotide LAR Depot in?

Octreotide LAR Depot has been evaluated in one completed clinical trial, NCT01707225, titled "Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)." The trial enrolled 10 participants in the United States and is now completed.